Clinicopathological features of mucoepidermoid carcinoma.
OBJECTIVE
We aimed to examine the clinical usefulness of a new World Health Organization classification scheme for salivary gland mucoepidermoid carcinoma, and to identify the factors most strongly associated with prognosis and outcome.


METHODS
The clinicopathological features of 45 patients who received treatment for mucoepidermoid carcinoma between 1986 and 2010 were retrospectively investigated.


RESULTS
The overall disease-specific 5-year survival rate was 81.8 per cent. The rate for patients with low-grade tumours (92.5 per cent) was significantly higher than that for patients with intermediate or high-grade tumours (52.2 per cent). Univariate analysis revealed that five factors were significantly associated with five-year survival: age, tumour stage classification, lymph node status, histological grade and treatment method. Four factors were significant in multivariate analysis: age, sex, tumour stage classification and lymph node status.


CONCLUSIONS
The new World Health Organization classification was useful in predicting disease progression in patients with mucoepidermoid carcinoma. Patients with high-grade tumours or other prognostic factors positively associated with disease progression should be carefully evaluated and monitored.
Niigata Prefecture Head and Neck Malignant Tumour Registration Committee, Faculty of Medicine, Niigata University, Japan.
K
K
Yamazaki
Niigata Prefecture Head and Neck Malignant Tumour Registration Committee, Faculty of Medicine, Niigata University, Japan.
H
H
Ohta
Niigata Prefecture Head and Neck Malignant Tumour Registration Committee, Faculty of Medicine, Niigata University, Japan.
R
R
Shodo
Niigata Prefecture Head and Neck Malignant Tumour Registration Committee, Faculty of Medicine, Niigata University, Japan.
H
H
Matsuyama
Niigata Prefecture Head and Neck Malignant Tumour Registration Committee, Faculty of Medicine, Niigata University, Japan.
S
S
Takahashi
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D018277:Carcinoma, Mucoepidermoid / Q000473:pathology* / Q000628:therapy; D015331:Cohort Studies; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000473:pathology / Q000628:therapy; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D010307:Parotid Neoplasms / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012468:Salivary Gland Neoplasms / Q000473:pathology* / Q000628:therapy; D012737:Sex Factors; D013365:Submandibular Gland Neoplasms / Q000473:pathology / Q000628:therapy; D055815:Young Adult